Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec 20:53:e20180498.
doi: 10.1590/0037-8682-0498-2018. eCollection 2019.

Pseudomonas aeruginosa in the ICU: prevalence, resistance profile, and antimicrobial consumption

Ághata Cardoso da Silva Ribeiro  1 , Márcia Terezinha Lonardoni Crozatti  1 , Adilson Aderito da Silva  2 , Rodrigo Spineli Macedo  3 , Antonia Maria de Oliveira Machado  4 , Antonio Távora de Albuquerque Silva  1
Affiliations

Pseudomonas aeruginosa in the ICU: prevalence, resistance profile, and antimicrobial consumption

Ághata Cardoso da Silva Ribeiro et al. Rev Soc Bras Med Trop. .

Abstract

Introduction: Pseudomonas aeruginosa is one of the main pathogens causing infection in intensive care units (ICUs) and usually presents antimicrobial resistance.

Methods: Data were obtained from ICUs between 2010 and 2013.

Results: P. aeruginosa had a prevalence of 14.5% of which 48.7% were multidrug resistant. We observed increasing resistance to carbapenems and polymyxin B and growing consumption of aminoglycosides, meropenem, ceftazidime, and polymyxin B. The regression impact between resistance and consumption was significant with respect to amikacin, imipenem, meropenem, and polymyxin B.

Conclusions: Monitoring antimicrobial consumption and resistant microorganisms should be reinforced to combat antimicrobial- and multi-drug resistance.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors declare that there are no conflicts of interest.

References

    1. World Health Organization (WHO) Antimicrobial Resistance. Global Report on surveillance. 1th ed. Geneva: WHO Press; 2014. [2018 Nov 22]. Available from: http://apps.who.int/iris/bitstream/handle/10665/112642/9789241564748_eng....
    1. Dereli N, Ozayar E, Degerli S, Sahin S, Koç F. Three-Year Evaluation of Nosocomial Infection Rates of the ICU. Braz J Anesthesiol. 2013;63(1):73–78. - PubMed
    1. Fraimow HS, Tsigrelis C. Antimicrobial Resistance in the Intensive Care Unit: Mechanisms, Epidemiology, and management of Specific Resistant Pathogens. Crit Care Clin. 2011;27(1):163–205. - PubMed
    1. Micek ST, Wunderink RG, Kollef MH, Chen C, Rello J, Chastre J, et al. An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance. Crit Care. 2015;19:219–227. - PMC - PubMed
    1. World Health Organization . Collaborating Centre for Drug Statistics Methodology - WHOCC. Norway: Norwegian Institute of Public Health; 2015. [2018 Nov 22]. Available from: http://www.whocc.no/atc_ddd_index/

MeSH terms

Substances